Carbonyl and oxidative stress in patients with breast cancer--is there a relation to the stage of the disease?
Jazyk angličtina Země Slovensko Médium print
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
17447853
Knihovny.cz E-zdroje
- MeSH
- estrogeny metabolismus MeSH
- karbonylace proteinů * MeSH
- krevní proteiny analýza MeSH
- lidé středního věku MeSH
- lidé MeSH
- lysin analogy a deriváty krev MeSH
- nádory prsu krev diagnóza terapie MeSH
- oxidace-redukce MeSH
- oxidační stres * MeSH
- produkty pokročilé glykace krev MeSH
- prognóza MeSH
- receptor erbB-2 metabolismus MeSH
- staging nádorů MeSH
- studie případů a kontrol MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- estrogeny MeSH
- krevní proteiny MeSH
- lysin MeSH
- N(6)-carboxymethyllysine MeSH Prohlížeč
- produkty pokročilé glykace MeSH
- receptor erbB-2 MeSH
UNLABELLED: Oxidative and carbonyl stress may, on one hand, contribute to the progression of cancer, on the other hand, they may have some antiproliferative effects. We examined serum levels of AGEs (advanced glycation end-products), CML (carboxymethyllysine) and AOPP (advanced oxidation protein products) in 86 patients with breast cancer subdivided based on the clinical stage (TNM classification), histologic grading, expression of hormonal and C-erb B2 receptors and in 14 healthy age-matched women as controls. Breast cancer patients had higher serum concentrations of AGEs (325,581 +/- 66,037 vs. 271,322 +/- 34,826 AU, p < 0.01) even in the early stage of the disease; patients with advanced breast cancer (stage III and IV) had significantly higher both AGEs and AOPP (113.0 +/- 44.9 vs. 78.1 +/- 28.4 micromol/l, p < 0.05) levels, not only compared to controls, but also compared to stages I and II. Serum levels of AOPP were higher in patients having only weakly positive expression of C-erb 2/Her-neu compared to controls and the patients having the highest C-erb2/Her-neu expression. Serum concentrations of AGEs in patients with breast cancer correlated with the age and also with the serum concentration of AOPP. IN CONCLUSION: breast cancer patients had an early increase of AGEs (marker of the carbonyl stress) followed by further increase of AGEs and elevation of AOPP (marker of oxidative stress) in patients with progressive disease. As the clinical significance of these observations is currently uncertain further studies are clearly warranted, especially with respect to their potential therapeutic implications.